Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT00844649 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00844649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00844649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2009
Completion date
April 9, 2013
Enrollment
861 (actual)
Sites
193

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer